290 related articles for article (PubMed ID: 9403621)
1. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling.
Fraccarollo D; Hu K; Galuppo P; Gaudron P; Ertl G
Circulation; 1997 Dec; 96(11):3963-73. PubMed ID: 9403621
[TBL] [Abstract][Full Text] [Related]
2. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
[TBL] [Abstract][Full Text] [Related]
3. ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats.
Oie E; Bjønerheim R; Grogaard HK; Kongshaug H; Smiseth OA; Attramadal H
Am J Physiol; 1998 Sep; 275(3):H868-77. PubMed ID: 9724291
[TBL] [Abstract][Full Text] [Related]
4. Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
Lee TM; Chen CC; Lin MS; Chang NC
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1871-9. PubMed ID: 18281380
[TBL] [Abstract][Full Text] [Related]
5. Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure.
Ding SS; Qiu C; Hess P; Xi JF; Clozel JP; Clozel M
Cardiovasc Res; 2002 Mar; 53(4):963-70. PubMed ID: 11922906
[TBL] [Abstract][Full Text] [Related]
6. Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
Tzanidis A; Lim S; Hannan RD; See F; Ugoni AM; Krum H
J Mol Cell Cardiol; 2001 May; 33(5):969-81. PubMed ID: 11343419
[TBL] [Abstract][Full Text] [Related]
7. Effects of nonselective endothelin-1 receptor antagonism on cardiac mast cell-mediated ventricular remodeling in rats.
Murray DB; Gardner JD; Brower GL; Janicki JS
Am J Physiol Heart Circ Physiol; 2008 Mar; 294(3):H1251-7. PubMed ID: 18178727
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure.
Iwanaga Y; Kihara Y; Inagaki K; Onozawa Y; Yoneda T; Kataoka K; Sasayama S
Circulation; 2001 Jul; 104(5):606-12. PubMed ID: 11479261
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs.
Choussat R; Hittinger L; Barbe F; Maistre G; Carayon A; Crozatier B; Su J
Cardiovasc Res; 1998 Sep; 39(3):580-8. PubMed ID: 9861300
[TBL] [Abstract][Full Text] [Related]
10. Aggravation of left ventricular remodeling by a novel specific endothelin ET(A) antagonist EMD94246 in rats with experimental myocardial infarction.
Hu K; Gaudron P; Schmidt TJ; Hoffmann KD; Ertl G
J Cardiovasc Pharmacol; 1998 Sep; 32(3):505-8. PubMed ID: 9733367
[TBL] [Abstract][Full Text] [Related]
11. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).
Teerlink JR; Löffler BM; Hess P; Maire JP; Clozel M; Clozel JP
Circulation; 1994 Nov; 90(5):2510-8. PubMed ID: 7955209
[TBL] [Abstract][Full Text] [Related]
12. Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats.
Oie E; Yndestad A; Robins SP; Børnerheim R; Asberg A; Attramadal H
Basic Res Cardiol; 2002 May; 97(3):239-47. PubMed ID: 12061394
[TBL] [Abstract][Full Text] [Related]
13. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
Hu K; Gaudron P; Anders HJ; Weidemann F; Turschner O; Nahrendorf M; Ertl G
Cardiovasc Res; 1998 Aug; 39(2):401-12. PubMed ID: 9798525
[TBL] [Abstract][Full Text] [Related]
14. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.
Zhang Y; Oliver JR; Horowitz JD
Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310
[TBL] [Abstract][Full Text] [Related]
15. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist.
Kaddoura S; Firth JD; Boheler KR; Sugden PH; Poole-Wilson PA
Circulation; 1996 Jun; 93(11):2068-79. PubMed ID: 8640984
[TBL] [Abstract][Full Text] [Related]
16. Effects of dual endothelin receptor blockade on sympathetic activation and arrhythmogenesis during acute myocardial infarction in rats.
Kolettis TM; Baltogiannis GG; Tsalikakis DG; Tzallas AT; Agelaki MG; Fotopoulos A; Fotiadis DI; Kyriakides ZS
Eur J Pharmacol; 2008 Feb; 580(1-2):241-9. PubMed ID: 18048027
[TBL] [Abstract][Full Text] [Related]
17. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
Sogni P; Moreau R; Gomola A; Gadano A; Cailmail S; Calmus Y; Clozel M; Lebrec D
Hepatology; 1998 Sep; 28(3):655-9. PubMed ID: 9731554
[TBL] [Abstract][Full Text] [Related]
18. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure.
Mulder P; Richard V; Bouchart F; Derumeaux G; Münter K; Thuillez C
Cardiovasc Res; 1998 Sep; 39(3):600-8. PubMed ID: 9861302
[TBL] [Abstract][Full Text] [Related]
19. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
Rondelet B; Kerbaul F; Motte S; van Beneden R; Remmelink M; Brimioulle S; McEntee K; Wauthy P; Salmon I; Ketelslegers JM; Naeije R
Circulation; 2003 Mar; 107(9):1329-35. PubMed ID: 12628956
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic effect of endothelin antagonists in dogs with myocardial infarction.
Ohta H; Suzuki J; Akima T; Kawai N; Hanada K; Nishikibe M
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S255-7. PubMed ID: 9595453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
